Atypical antipsychotic drugs and diabetes mellitus in a large outpatient population: A retrospective cohort study

Pharmacoepidemiology and Drug Safety

Volumn 14, Issue 6, 2005, Pages 407-415

  Østbye, Truls ^a   Curtis, Lesley H ^a   Masselink, Leah E ^a   Hutchison, Steve ^b   Wright, Alan ^c   Dans, Peter E ^c   Schulman, Kevin A ^a   Krishnan, Ranga R ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b AdvancePCS   (United States)

^c AdvancePCS Clinical Services   (United States)

Author keywords

Antipsychotic agents; Cohort studies; Diabetes mellitus; Insurance; Pharmaceutical services; Pharmacoepidemiology; Prescriptions, drug

Indexed keywords

ACARBOSE; ACETOHEXAMIDE; ACETOPHENAZINE; AMFEBUTAMONE; AMITRIPTYLINE; AMOXAPINE; ANTIBIOTIC AGENT; ANTIDEPRESSANT AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; CHLORDIAZEPOXIDE; CHLORPROMAZINE; CHLORPROPAMIDE; CHLORPROTHIXENE; CITALOPRAM; CLOMIPRAMINE; CLOZAPINE; DESIPRAMINE; DOXEPIN; FLUOXETINE; FLUPHENAZINE; FLUVOXAMINE; GLIBENCLAMIDE; GLIMEPIRIDE; GLIPIZIDE; HALOPERIDOL; IMIPRAMINE; INSULIN; ISOCARBOXAZID; LOXAPINE; MAPROTILINE; MESORIDAZINE; METFORMIN; MIRTAZAPINE; MOLINDONE; NEFAZODONE; NEUROLEPTIC AGENT; NORTRIPTYLINE; OLANZAPINE; ORAL ANTIDIABETIC AGENT; PAROXETINE; PERPHENAZINE; PHENELZINE; PROCHLORPERAZINE; PROMAZINE; PROTRIPTYLINE; QUETIAPINE; REPAGLINIDE; RISPERIDONE; ROSIGLITAZONE; SERTRALINE; THIORIDAZINE; TIOTIXENE; TOLAZAMIDE; TOLBUTAMIDE; TRANYLCYPROMINE; TRAZODONE; TRIFLUOPERAZINE; TRIFLUPROMAZINE; TRIMIPRAMINE; VENLAFAXINE; ZIPRASIDONE;

ADOLESCENT; ADULT; AGE; AGED; ARTICLE; CHILD; CHRONIC DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; HUMAN; INCIDENCE; INFANT; MAJOR CLINICAL STUDY; MALE; OUTPATIENT; PRESCRIPTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; SCORING SYSTEM; SEX DIFFERENCE;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CLOZAPINE; COHORT STUDIES; DATABASES, FACTUAL; DIABETES MELLITUS; DIBENZOTHIAZEPINES; FEMALE; HUMANS; INCIDENCE; INSURANCE CLAIM REPORTING; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; OUTPATIENTS; PIPERAZINES; PRESCRIPTIONS, DRUG; RETROSPECTIVE STUDIES; RISPERIDONE; SEX FACTORS; THIAZOLES; THIORIDAZINE; TIME FACTORS; UNITED STATES;

EID: 21244475081     PISSN: 10538569     EISSN: None     Source Type: Journal    
DOI: 10.1002/pds.1016     Document Type: Article

References (38)

1. Glick ID, Murray SR, Vasudevan P, Marder SR, Hu RJ. Treatment with atypical antipsychotics: new indications and new populations. J Psychiatr Res 2001; 35: 187-191.
2. The National Institute for Health Care Management Research and Educational Foundation. Prescription Drug Expenditures in 2001: Another Year of Escalating Costs. NICHM Foundation; 2002. Available at: http://www.nihcm.org/spending2001.pdf. [Accessed 8 October 2003].
3. Leucht S, Pitschel-Walz G, Abraham D, Kissling W. Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo: a meta-analysis of randomized controlled trials. Schizophr Res 1999; 35: 51-68.
4. Kinon BJ, Basson BR, Gilmore JA, Tollefson GD. Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia. J Clin Psychiatry 2001; 62: 92-100.
5. Allison DB, Mentore JL, Heo M, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999; 156: 1686-1696.
6. Koller E, Schneider B, Bennett K, Dubitsky G. Clozapine-associated diabetes. Am J Med 2001; 111: 716-723.
7. Wirshing DA, Spellberg BJ, Erhart SM, Marder SR, Wirshing WC. Novel antipsychotics and new onset diabetes. Biol Psychiatry 1998; 44: 778-783.
8. Hagg S, Joelsson L, Mjorndal T, Spigset O, Oja G, Dahlqvist R. Prevalence of diabetes and impaired glucose tolerance in patients treated with clozapine compared with patients treated with conventional depot neuroleptic medications. J Clin Psychiatry 1998; 59: 294.
9. Kamran A, Doraiswamy PM, Jane JL, Hammett EB, Dunn L. Severe hyperglycemia associated with high doses of clozapine. Am J Psychiatry 1994; 151: 1395.
10. Bettinger TL, Mendelson SC, Dorson PG, Crismon ML. Olanzapine-induced glucose dysregulation. Ann Pharmacother 2000; 34: 865-867.
11. Croarkin PE, Jacobs KM, Bain BK. Diabetic ketoacidosis associated with risperidone treatment? Psychosomatics 2000; 41: 369-370.
12. Henderson DC, Cagliero E, Gray C, et al. Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: a five-year naturalistic study. Am J Psychiatry 2000; 157: 975-981.
13. Maule S, Giannella R, Lanzio M, Villari V. Diabetic ketoacidosis with clozapine treatment. Diabet Nutr Metab 1999; 12: 187-188.
14. Sobel M, Jaggers ED, Franz MA. New-onset diabetes mellitus associated with the initiation of quetiapine treatment. J Clin Psychiatry 1999; 60: 556-557.
15. Lindenmayer JP, Patel R. Olanzapine-induced ketoacidosis with diabetes mellitus. Am J Psychiatry 1999; 156: 1471.
16. Goldstein LE, Sporn J, Brown S, et al. New-onset diabetes mellitus and diabetic ketoacidosis associated with olanzapine treatment. Psychosomatics 1999; 40: 438-443.
17. Sobel M, Jaggers ED, Franz MA. New-onset diabetes mellitus associated with the initiation of quetiapine treatment. J Clin Psychiatry 1999; 60: 556-557.
18. Hagg S, Joelsson L, Mjorndal T, Spigset O, Oja G, Dahlqvist R. Prevalence of diabetes and impaired glucose tolerance in patients treated with clozapine compared with patients treated with conventional depot neuroleptic medications. J Clin Psychiatry 1998; 59: 294-299.
19. Popli AP, Konicki PE, Jurjus GJ, Fuller MA, Jaskiw GE. Clozapine and associated diabetes mellitus. J Clin Psychiatry 1997; 58: 108-111.
20. Bettinger TL, Mendelson SC, Dorson PG, Crismon ML. Olanzapine-induced glucose dysregulation. Ann Pharmacother 2000; 34: 865-867.
21. Procyshyn RM, Pande S, Tse G. New-onset diabetes mellitus associated with quetiapine. Can J Psychiatry 2000; 45: 668-669.
22. Rigalleau V, Gatta B, Bortnaud S, et al. Diabetes as a result of atypical antipsychotic drugs - a report of three cases. Diabet Med 2000; 17: 484-486.
23. Lund BC, Perry PJ, Brooks JM, Arndt S. Clozapine use in patients with schizophrenia and the risk of diabetes, hyperlipidemia, and hypertension: a claims-based approach. Arch Gen Psychiatry 2001; 58: 1172-1176.
24. Gianfrancesco FD, Grogg AL, Mahmoud RA, Wang RH, Nasrallah HA. Differential effects of risperidone, olanzapine, clozapine, and conventional antipsychotics on type 2 diabetes: findings from a large health plan database. J Clin Psychiatry 2002; 63: 920-930.
25. Koro CE, Fedder DO, L'Italien GJ, et al. Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case-control study. Br Med J 2002; 325: 243.
26. Buse JB, Cavazzoni P, Hornbuckle K, Hutchins D, Breier A, Jovanovic L. A retrospective cohort study of diabetes mellitus and antipsychotic treatment in the United States. J Clin Epidemiol 2003; 56: 164-170.
27. Koller E, Malozowski Doraiswamy PM. Atypical antipsychotic drugs and hyperglycemia in adolescents. JAMA 2001; 286: 2547-2548.
28. Von Korff M, Wagner EH, Saunders K. A chronic disease score from automated pharmacy data. J Clin Epidemiol 1992; 45: 197-203.
29. Clark DL, VonKorff M, Saunders K, Baluch WM, Simon GE. A chronic disease score with empirically derived weights. Med Care 1995; 33: 783-795.
30. Parker JP, McCombs JS, Graddy EA. Can pharmacy data improve prediction of hospital outcomes? Comparisons with a diagnosis-based comorbidity measure. Med Care 2003; 41: 407-419.
31. Ryan MC, Thakore JH. Physical consequences of schizophrenia and its treatment: the metabolic syndrome. Life Sci 2002; 71: 239-257.
32. Caro JJ, Ward A, Levinton C, Robinson K. The risk of diabetes during olanzapine use compared with risperidone use: a retrospective database analysis. J Clin Psychiatry 2002; 63: 1135-1139.
33. Wang PS, Glynn RJ, Ganz DA, Schneeweiss S, Levin R, Avorn J. Clozapine use and risk of diabetes mellitus. J Clin Psychopharmacol 2002; 22: 236-243.
34. Newcomer JW, Haupt DW, Fucetola R, et al. Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia. Arch Gen Psychiatry 2002; 59: 337-345.
35. Tamblyn R, Lavoei G, Petrella L, Monette J. The use of prescription claims databases in pharmacoepidemiological research: the accuracy and comprehensiveness of the prescription claims database in Quebec. J Clin Epidemiol 1995; 48: 999-1009.
36. Kirking DM, Ammann MA, Harrington CA. Comparison of medical records and prescription claims files in documenting prescription medication therapy. J Pharmacoepidemiol 1996; 5: 3-15.
37. Schneeweiss S, Seeger JD, Maclure M, Wang PS, Avorn J, Glynn RJ. Performance of comorbidity scores to control for confounding in epidemiological studies using claims data. Am J Epidemiol 2001; 154: 854-864.
38. Centers for Disease Control and Prevention. Prevalence and indicidence. In National Center for Chronic Disease Prevention and Health Promotion. Diabetes Public Health Resource - Statistics: 1999 Surveillance Report. Centers for Disease Control and Prevention: Atlanta, GA, 1999. Available at: http://www.cdc.gov/diabetes/statistics/survl99/chap2/. [Accessed 8 October 2003].